# Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours

> **NCT01581060** · PHASE1,PHASE2 · TERMINATED · sponsor: **Heidelberg Pharma AG** · enrollment: 41 (actual)

## Conditions studied

- Advanced Solid Tumours

## Interventions

- **DRUG:** WX-554

## Key facts

- **NCT ID:** NCT01581060
- **Lead sponsor:** Heidelberg Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-03
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Study terminated for business reasons
- **Last updated:** 2014-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01581060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01581060, "Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01581060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*